Press release
Amyloidosis Market to Accelerate Substantially by 2032, estimates DelveInsight
Key Takeaways from the Amyloidosis Market Research Report
* The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
* As per DelveInsight analysis, the Amyloidosis Market is anticipated to witness growth at a considerable CAGR.
* The leading Amyloidosis Companies working in the market include Attralus Inc., Novotech Pty Limited, Criterium Inc., Amgen, Millennium Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Intellia Therapeutiscs, Regeneron Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline, United BioSource LLC, and others
* Promising Amyloidosis Therapies in the various stages of development include AT-02, Carfilzomib, Dexamethasone, VELCADE, NTLA-2001, GSK2398852, Eplontersen, and others.
* April 2024:- Attralus Inc.- A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects With Systemic Amyloidosis to Assess the Safety, Tolerability, and Pharmacokinetics of AT-02. This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
* April 2024:- Intellia Therapeutics- MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM). To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
* April 2024:- Akcea Therapeutics- A Prospective, Non-interventional, Long-term, Multinational Cohort Safety Study of Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (hATTR-PN). This is a prospective, non-interventional, Long-term, multinational cohort safety study of patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-PN). The overarching goal of this study is to further characterize the long-term safety of TEGSEDI (inotersen) in patients with hATTR-PN under real-world conditions.
Discover which therapies are expected to grab the Amyloidosis Market Share @ Amyloidosis Market Outlook [https://www.delveinsight.com/sample-request/amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Amyloidosis Overview
Amyloidosis is a group of diseases characterized by the abnormal buildup of a protein called amyloid in various organs and tissues of the body. Amyloid is a protein that normally circulates in the blood, but in amyloidosis, it becomes misfolded and clumps together to form insoluble fibers. These fibers can accumulate in different organs such as the heart, kidneys, liver, spleen, nervous system, and digestive tract, interfering with their normal function and leading to organ damage and failure.
Amyloidosis Epidemiology Insights
The epidemiology section of Amyloidosis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Amyloidosis Epidemiology trends @ Amyloidosis Epidemiological Insights [https://www.delveinsight.com/sample-request/amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Amyloidosis Drugs Market
The Amyloidosis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Amyloidosis signaling in Amyloidosis are likely to uncover new therapeutic targets and further expand treatment options for patients.
Amyloidosis Treatment Market Landscape
The Amyloidosis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Amyloidosis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Amyloidosis treatment guidelines, visit @ Amyloidosis Treatment Market Landscape [https://www.delveinsight.com/sample-request/amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Amyloidosis Market Outlook
The report's outlook on the Amyloidosis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Amyloidosis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Amyloidosis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Amyloidosis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.
Amyloidosis Drugs Uptake
The drug chapter of the Amyloidosis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Amyloidosis.
Major Amyloidosis Companies
Several Amyloidosis Companies working in the market include Attralus Inc., Novotech Pty Limited, Criterium Inc., Amgen, Millennium Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Intellia Therapeutics, Regeneron Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline, United BioSource LLC, and others
Learn more about the FDA-approved drugs for Amyloidosis @ Drugs for Amyloidosis Treatment [https://www.delveinsight.com/sample-request/amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Amyloidosis Market Report
* Coverage- 7MM
* Amyloidosis Companies- Attralus Inc., Novotech Pty Limited, Criterium Inc., Amgen, Millennium Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Intellia Therapeutiscs, Regeneron Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline, United BioSource LLC, and others
* Amyloidosis Therapies- AT-02, Carfilzomib, Dexamethasone, VELCADE, NTLA-2001, GSK2398852, Eplontersen, and others.
* Amyloidosis Market Dynamics: Amyloidosis Market Drivers and Barriers
* Amyloidosis Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Amyloidosis Drugs in development @ Amyloidosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Executive Summary
3. Competitive Intelligence Analysis
4. Amyloidosis: Market Overview at a Glance
5. Amyloidosis: Disease Background and Overview
6. Patient Journey
7. Amyloidosis Epidemiology and Patient Population
8. Amyloidosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Amyloidosis Unmet Needs
10. Key Endpoints of Amyloidosis Treatment
11. Amyloidosis Marketed Products
12. Amyloidosis Emerging Therapies
13. Amyloidosis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Amyloidosis
17. KOL Views
18. Amyloidosis Market Drivers
19. Amyloidosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=amyloidosis-market-to-accelerate-substantially-by-2032-estimates-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Amyloidosis Market to Accelerate Substantially by 2032, estimates DelveInsight here
News-ID: 3475567 • Views: …
More Releases from ABNewswire
Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Outdoor living has evolved to become something more.
It is now a lifestyle choice.
Today's families seek spaces that harmonize with the natural world, yet remain as comfortable and well-designed as rooms in their homes. Patios and pergolas aren't an afterthought, but an absolute must that adds significant value to your property and makes everyday life better.
In areas with seasonal weather, where people can be outside for most of the year, homeowners…
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecede …
Dash Capital's expansion in Detroit reflects strong demand from local businesses for flexible, fast funding solutions that support growth and operational needs across the Motor City's diverse economic landscape.
The Detroit business landscape continues to show remarkable resilience and growth potential, prompting Dash Capital to expand its funding programs in response to overwhelming demand from local entrepreneurs. This expansion comes at a time when Motor City businesses are actively seeking alternative…
Jacksonville Family Business Expands Concrete Washing Services Amid Growing Prop …
Nubirth Pressure Washing, a family-owned company serving Jacksonville since 2004, reflects the growing demand for specialized exterior property cleaning in Northeast Florida, offering comprehensive surface restoration services.
Jacksonville, FL - The Northeast Florida property maintenance industry has witnessed significant growth in specialized cleaning services as homeowners and businesses prioritize exterior property care. Local family-owned company Nubirth Pressure Washing [https://www.google.com/maps/place/Nubirth+Pressure+Washing/@30.3340387,-81.7122184,17z/data=!3m1!4b1!4m6!3m5!1s0x88e5b9c01d715555:0xd2c2470a4640f2be!8m2!3d30.3340387!4d-81.7122184!16s%2Fg%2F11vk2l_v57!5m1!1e3?entry=ttu&g_ep=EgoyMDI1MDgyNS4wIKXMDSoASAFQAw%3D%3D] represents this trend, having served the Jacksonville area since 2004 with comprehensive…
A-Class Moving & Storage Expands Direct Delivery Network, Positioning Miramar Mo …
A-Class Moving & Storage, based in Miramar, has expanded its direct delivery network across South Florida, strengthening its position as a leading moving company and reliable alternative to traditional van line brokers. The growth allows the family-owned business to serve more customers while preserving its personalized service standards.
A-Class Moving & Storage has announced a significant expansion of its direct delivery network throughout South Florida, establishing the business as a leading…
More Releases for Amyloid
Islet Amyloid Polypeptide Market Analysis Current Landscape and Future Outlook
The global Islet Amyloid Polypeptide market is projected to reach approximately USD 255.8 million by 2033, growing at a compound annual growth rate (CAGR) of 10.1% from 2024 to 2033.
Islet Amyloid Polypeptide Market Overview
The Islet Amyloid Polypeptide market is gaining traction due to its critical role in metabolic disorders, particularly in type 2 diabetes research and treatment. Islet Amyloid Polypeptide (IAPP), also known as amylin, is closely associated with insulin…
Cerebral Amyloid Angiopathy Pipeline Landscape: 10+ Emerging Therapies Targeting …
Cerebral Amyloid Angiopathy (CAA) is a progressive cerebral small vessel disease marked by amyloid-β (Aβ) protein deposition in the walls of leptomeningeal and cortical blood vessels. Often occurring in the elderly and closely linked with Alzheimer's disease, CAA contributes significantly to cognitive impairment, spontaneous intracerebral hemorrhage, and cerebral microbleeds. Despite its high clinical burden, there are currently no approved disease-modifying therapies specifically for CAA, and diagnosis remains challenging without advanced…
Amyloid Peptides Market to Witness Astonishing Growth by 2029
Amyloid Peptides Market is anticipated to grow at a significant CAGR during the forecast period. Growing favourable investment, as well as reimbursement facilities in the developed economic countries, is one of the major factors that is expected to fuel the global amyloid peptides market during the forecast period. Moreover, a growing number of clinical trials and research activities to develop treatment and drugs for Alzheimer's are also anticipated to boost…
Amyloid Peptides Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Amyloid Peptides Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Amyloid Peptides players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amyloid Peptides with respect to individual growth…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
